Main Article Content
Acne, PROSES, sarecycline, antibiotics, Real World Evidence, RWE
Introduction: The objective of this analysis was to evaluate facial IGA and the associated IGA success, stratified by age and gender, among AV patients administered sarecycline in community practices across the U.S.
Methods: A single-arm, prospective cohort study (PROSES) was conducted with moderate-to-severe non-nodular AV patients >9 years who were prescribed sarecycline in real-world community practices in the US. Facial IGA of AV status was collected on a five-point adjectival response scale (0(clear)-4(severe)). IGA success at week-12 was defined as >2-grade improvement and score 0-clear or 1-almost clear at week-12. Proportion of patients achieving IGA success was analyzed, stratified by gender and age (9-17yrs, >=18yrs).
Results: A total of 253 AV patients completed the study (female: 66.40%; 9-17yrs: 39.92%; >=18yrs: 60.08%; Facial IGA success at week-12 was 56.47% for male and 60.12% for female; 57.43% for patients 9-17yrs old and 59.87% for patients >=18yrs old.
Conclusion: Within the study cohort of adolescent and adult patients with moderate to severe AV at baseline administered sarecycline, a narrow-spectrum, tetracycline-derived antibiotic for 12 weeks, across the gender and age groups, majority of patients achieved IGA success at week-12.